Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

dehydroftorafur 2Taxes 2Radiotherapy 2Radiation 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Capecitabine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Adenocarcinoma × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT07240766 2026-02-13

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Zhejiang University

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT07080021 2025-07-29

MRD

Ruijin Hospital

Recruiting
119 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT03970252 2024-08-09

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
28 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT02394535 2022-09-02

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
25 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡